Akari Therapeutics PLC (AKTX) — DEF 14A Filings
All DEF 14A filings from Akari Therapeutics PLC. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Akari Therapeutics Seeks Share Restructuring, Warrant Approval
— Nov 17, 2025 Risk: high
Akari Therapeutics Plc (AKTX) is holding a General Meeting on December 15, 2025, to address several critical resolutions impacting its share structure and futur -
Akari Therapeutics Details Equity-Heavy Executive Pay in DEF 14A
— Jun 6, 2025 Risk: medium
Akari Therapeutics Plc's DEF 14A filing primarily details executive compensation and equity award information for the fiscal year ending December 31, 2024, and -
Akari Therapeutics Plc Files Definitive Proxy Statement
— Jun 3, 2024 Risk: low
Akari Therapeutics Plc filed a definitive proxy statement (DEF 14A) on June 3, 2024, for its annual general meeting. The filing details the company's governance
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX